Today: 20 May 2026
Browse Category

Health News 12 August 2025 - 25 November 2025

Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco Issues Urgent Recall of Caesar Salad and Chicken Sandwich Over Plastic Contamination Risk (November 25, 2025)

Costco has recalled its prepared Caesar Salad (item #19927) and Chicken Sandwich with Caesar Salad (item #11444) after plastic fragments were found in dressing packets supplied by Ventura Foods. The recall covers products sold in select Midwest, Northeast, and Southeast warehouses with sell-by dates from October 17 to November 9, 2025. Members are urged to check refrigerators for leftover dressing packets.
25 November 2025
·
Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

Yoplait YOP Drinkable Yogurt Recall in Canada: Full List of Affected Products, Best-Before Dates and What Shoppers Should Do – November 24, 2025

The Canadian Food Inspection Agency has recalled all flavours of Yoplait YOP 200 mL drinkable yogurt nationwide due to possible plastic contamination. The recall, issued November 22, is classified as Class 1, CFIA’s highest risk level. No injuries or illnesses have been reported. The recall covers single bottles and multi-packs with best-before dates up to January 1.
24 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia said a patient in its Phase 3 MAGNITUDE trial died after severe liver toxicity; FDA clinical holds on MAGNITUDE and MAGNITUDE-2 remain. NTLA shares fell as RBC cut its price target to $9, citing increased risk. The company reported $669.9 million in cash and securities, expecting its runway to last into mid-2027. Work continues on its hereditary angioedema program.
7 November 2025
···
Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

The FDA on Oct. 14 classified the recall of millions of eggs from Arkansas’ Black Sheep Egg Co. and Texas’ Kenz Henz as Class I, the highest severity, after inspectors found salmonella in 40 samples at Black Sheep’s plant. No illnesses have been reported. The recall affects Black Sheep and Kenz Henz eggs distributed in several states. Consumers are urged not to eat or sell the recalled eggs and to sanitize surfaces.
22 October 2025
·
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences shares jumped over 20% in pre-market trading Friday after receiving an FDA Commissioner’s National Priority Voucher for its lead drug, cytisinicline. The FDA also accepted Achieve’s New Drug Application for cytisinicline as a smoking cessation treatment, with a decision expected by June 2026. ACHV stock reached multi-month highs near $3 following the news. The company’s market cap is about $160 million.
17 October 2025
··
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility shares surged 89.6% to $1.43 on Oct. 16, with intraday highs of $2.03 and over 108 million shares traded—far above its 5.5 million share float. The rally follows a $200,000 preferred share sale and a recent SEC filing to register 8.35 million shares for resale. The company remains unprofitable and faces liquidity pressures. Year-to-date, the stock is up 95% but still trades 98% below its 52-week high.
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences shares jumped over 250% intraday on Oct. 6, 2025, after the FDA granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfa, for Sanfilippo Syndrome Type B. The stock rose from around $9 to $31. Spruce regained its Nasdaq listing in September following a reverse split. The company reported $16.4 million in cash as of June 30 and remains unprofitable.
6 October 2025
··
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

The XFG (“Stratus”) COVID variant accounted for about 67% of global sequences by late August 2025, according to WHO. The agency classifies XFG as a Variant Under Monitoring with low added public-health risk. Most cases remain mild in vaccinated people. U.S. CDC reports overall COVID activity is declining, with XFG now dominant in wastewater data.
28 September 2025
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

The FDA approved updated COVID-19 boosters from Pfizer and Moderna but restricted them to seniors and high-risk groups, excluding healthy children. Infectious disease experts warned the move could leave millions unprotected. The CDC director was fired after refusing to follow anti-vaccine directives, triggering mass resignations among top officials.
29 August 2025
·
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s melanoma vaccine Cylembia plus Merck’s Keytruda missed statistical significance in Phase 3, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. The FDA approved PharmaTher’s ketamine (KETARx) for anesthesia and pain. A dengue outbreak in Pacific Island nations has infected over 16,500 and killed 17 in 2025, with Fiji, Samoa, and Tonga hardest hit.
12 August 2025
1 2 3 4

Stock Market Today

  • NVIDIA Options Signal 6.1% Post-Earnings Price Move
    May 20, 2026, 1:57 PM EDT. NVIDIA (NVDA) options trading before earnings shows normal volumes, with call options outnumbering puts by over two to one. Implied volatility, a measure of expected stock price fluctuations derived from option prices, indicates the market expects a significant move around 6.1%, roughly $13 per share, following the earnings report. This level of implied volatility reflects investor anticipation of substantial price action, influenced by earnings results and company outlook. Such expectations guide traders on potential market reactions and inform hedging strategies ahead of NVIDIA's earnings announcement.

Latest articles

BlackBerry Stock Nears Highs as Traders Eye Government Moves

BlackBerry Stock Nears Highs as Traders Eye Government Moves

20 May 2026
BlackBerry’s U.S.-listed shares rose 0.5% to $6.24 after its AtHoc platform renewed a high-level U.S. government cloud-security certification. Trading volume topped 27 million shares, with prices ranging from $6.10 to $6.37. The company’s QNX business reported 20% revenue growth last quarter. Executives are scheduled to speak at a Toronto tech conference Thursday.
Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn

Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn

20 May 2026
Archer Aviation shares were flat near $5.94 Wednesday afternoon as SEC filings showed executives sold stock to cover tax withholding on vested shares. The company registered over 3.2 million shares for resale and plans to issue up to $8 million in stock to vendors. Archer reported a $217.7 million net loss in Q1 and ended the quarter with $1.8 billion in liquidity.
IREN Stock Surges as Nvidia Fever Returns — But the AI Cloud Bet Has a Catch

IREN Stock Surges as Nvidia Fever Returns — But the AI Cloud Bet Has a Catch

20 May 2026
IREN Limited shares rose 9.4% to $52.23 on Wednesday, trading over 23 million shares as investors awaited Nvidia’s earnings. IREN recently signed a $3.4 billion AI cloud contract with Nvidia and closed a $3 billion convertible-note offering. The company reported a quarterly net loss of $247.8 million on revenue of $144.8 million, down from the prior quarter.
Go toTop